Education
About Us
Working with TipRanks
Follow Us
Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
TRIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $3.44
Previous CloseN/A
Volume141.89K
Average Volume (3M)9.11M
Market Cap
$20.58M
Enterprise Value$102.30M
Total Cash (Recent Filing)$5.17M
Total Debt (Recent Filing)$100.76M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Dec 11, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jun 05, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,632,019
10 Day Avg. Volume134,639
30 Day Avg. Volume9,112,540
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.97
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit4.89
Enterprise Value/Ebitda-6.05
Forecast
1Y Price Target
$1.50Price Target Upside32.74% Upside
Rating ConsensusHold
Number of Analyst Covering0
Trinity Biotech News
TRIB FAQ
What was Trinity Biotech Plc’s price range in the past 12 months?
Trinity Biotech Plc lowest stock price was $0.48 and its highest was $3.44 in the past 12 months.
What is Trinity Biotech Plc’s market cap?
Trinity Biotech Plc’s market cap is $20.58M.
When is Trinity Biotech Plc’s upcoming earnings report date?
Trinity Biotech Plc’s upcoming earnings report date is Dec 11, 2025 which is in 76 days.
How were Trinity Biotech Plc’s earnings last quarter?
Currently, no data Available
Is Trinity Biotech Plc overvalued?
According to Wall Street analysts Trinity Biotech Plc’s price is currently Undervalued.
Does Trinity Biotech Plc pay dividends?
Trinity Biotech Plc pays a Annually dividend of $1.1 which represents an annual dividend yield of N/A. See more information on Trinity Biotech Plc dividends here
What is Trinity Biotech Plc’s EPS estimate?
Trinity Biotech Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Trinity Biotech Plc have?
Trinity Biotech Plc has 18,632,019 shares outstanding.
What happened to Trinity Biotech Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Trinity Biotech Plc?
Currently, no hedge funds are holding shares in TRIB
Trinity Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (32.74% Upside)
$1.50 (32.74% Upside)
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 11.9%
Last 30 Days ▼ 11.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.80%
12-Months-Change
Fundamentals
Return on Equity
77.20%
Trailing 12-Months
Asset Growth
10.50%
Trailing 12-Months
Company Description
Trinity Biotech Plc
Trinity Biotech is a biotechnology company that specializes in the development, manufacture, and marketing of diagnostic products for the healthcare sector. Operating primarily in the fields of infectious diseases, autoimmune diseases, and diabetes, Trinity Biotech offers a wide range of diagnostic testing solutions, including both rapid tests and laboratory-based assays. The company's core products include enzyme-linked immunosorbent assays (ELISA), point-of-care tests, and other diagnostic kits designed for use in hospitals, laboratories, and clinics worldwide.
Technical Analysis
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
12.80% Other Institutional Investors
87.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---